Summary - ASND - NASDAQ - Weiss Ratings

D

Ascendis Pharma A/S ASND

$168.84 $15.8610.37%

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$111.09 - $158.00

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

--

Headlines

Ascendis Pharma A/S (ASND, $168.84) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 17, 2025

3/18/2025 - Tickeron - Stocks

Ascendis Pharma A/S (ASND, $152.98) Stochastic Oscillator left the overbought zone on March 14, 2025

3/15/2025 - Tickeron - Stocks

Ascendis Pharma A/S (ASND, $150.31) Stochastic Oscillator left the oversold zone on March 12, 2025

3/13/2025 - Tickeron - Stocks

Optimistic Investors Push Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 26% But Growth Is Lacking

3/13/2025 - Simply Wall St

Victory Capital Management Inc. Sells 2,505 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

3/12/2025 - MarketBeat

Ascendis Pharma A/S (ASND, $138.18) Stochastic Oscillator left the oversold zone on March 10, 2025

3/11/2025 - Tickeron - Stocks

Ascendis Pharma A/S (ASND, $138.18) Stochastic Oscillator left the oversold zone on March 10, 2025

3/11/2025 - Tickeron - Stocks

Ascendis Pharma A/S (ASND, $145.74) price may climb as it broke lower Bollinger Band on Mar 07, 2025

3/8/2025 - Tickeron - Stocks

Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Candriam S.C.A.

3/7/2025 - MarketBeat

12,528 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by Proficio Capital Partners LLC

3/7/2025 - MarketBeat

Candriam S.C.A. Has $38.57 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

3/6/2025 - Ticker Report

Ascendis Pharma A/S (ASND, $151.93) RSI Indicator left the overbought zone on March 03, 2025

3/4/2025 - Tickeron - Stocks

Ascendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High - Here's Why

3/2/2025 - MarketBeat

Ascendis Pharma A/S (NASDAQ:ASND) Position Reduced by Henry James International Management Inc.

3/1/2025 - Ticker Report

Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of "Moderate Buy" by Analysts

2/28/2025 - MarketBeat

Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Handelsbanken Fonder AB

2/26/2025 - MarketBeat

Cantor Fitzgerald Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock

2/25/2025 - Ticker Report

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $200.00 at Cantor Fitzgerald

2/25/2025 - MarketBeat

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

2/24/2025 - Globe Newswire

New York State Common Retirement Fund Acquires 25,164 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

2/21/2025 - MarketBeat

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00 at Evercore ISI

2/19/2025 - MarketBeat

Ascendis Pharma A/S (NASDAQ:ASND) Given New $260.00 Price Target at Evercore ISI

2/18/2025 - Ticker Report

Rice Hall James & Associates LLC Has $22.56 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

2/18/2025 - MarketBeat

Q1 EPS Estimates for Ascendis Pharma A/S Lowered by Wedbush

2/17/2025 - MarketBeat

Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results: Here's What Analysts Are Forecasting For This Year

2/15/2025 - Simply Wall St

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Wednesday, February 12, 2025

Period Date

Tuesday, December 31, 2024

Next Filing

Beginning of May (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Sep 12, 2024 - $111.09

52-week High

Mar 03, 2025 - $158.00

Valuation

Market Cap

$9.15B - Mid Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

ascendispharma.com

Phone Number

45 70 22 22 44

Address

Tuborg Boulevard 12
Hellerup, 2900

Country

Year Founded

Business Description

Sector

--

Industry

--

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The... more